Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alan Kramer

Rheumatology Suwanee, GA Medical Doctor

NPI 1144216656 CMS profile 6915

3340 Paddocks Pkwy, Suwanee, GA 30024

Open in the dashboard

General payments

$834

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alan Kramer of Suwanee, GA is reported in the CMS Open Payments database as having received $834 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2024 General $42 2
2023 General $26 1
2022 General $15 1
2021 General $363 27
2020 General $92 6
2019 General $269 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Kramer
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Alan Kramer were reported at $28. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Alan Kramer Rheumatology median Middle half National median
2019 $269 $744 $153–$2,687 $163
2020 $92 $462 $98–$2,027 $114
2021 $363 $531 $101–$2,153 $132
2022 $15 $627 $125–$2,303 $149
2023 $26 $741 $145–$2,524 $160
2024 $42 $830 $166–$2,660 $164
2025 $28 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $181 12 payments
  2. Novartis Pharmaceuticals Corporation $150 14 payments
  3. Gilead Sciences, Inc. $95 4 payments
  4. Amgen Inc. $73 4 payments
  5. Sanofi-Aventis U.S. LLC $65 1 payment
  6. Horizon Therapeutics plc $59 3 payments
  7. Pfizer Inc. $48 3 payments
  8. Novo Nordisk Inc $29 2 payments
  9. Aurinia Pharma U.S., Inc. $20 1 payment
  10. Antares Pharma, Inc. $19 1 payment
  11. Other $95 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $769 50 payments
  2. Education $65 1 payment
Products named General payments · program years 2019–2025
  1. COSENTYX $264 25 payments
  2. RINVOQ $92 6 payments
  3. HUMIRA $77 5 payments
  4. KEVZARA $65 1 payment
  5. RAYOS Rayos $59 3 payments
  6. RAYOS Rayos $59 3 payments
  7. RAYOS Rayos $59 3 payments
  8. XELJANZ $48 3 payments
  9. Prolia $37 2 payments
  10. Enbrel $36 2 payments
  11. Other $242 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record